-Advertisement-
-Advertisement-
Presbyopia
Orasis Pharmaceuticals submits NDA for novel eye drop for presbyopia treatment
Orasis Pharmaceuticals announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%). In the Phase 3 NEAR-1 and NEAR-2 clinical trials evaluating CSF-1, the primary and key secondary endpoints were met. The most common treatment-related...
Read More-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
Videos
12 Dec, 2022
Mark Dlugoss: Vision correction has evolved over the years from...
-Advertisement-
-Advertisement-
Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved